Invokana Lawsuit and FDA Bone Fracture Warnings Cause Concern Over SGLT2 Inhibitor Drugs

March 18, 2016 – – TheProductLawyers.com reports on a public safety communication issued by the U.S. Food and Drug Administration (FDA) which discussed new-generation, type-2 diabetes drugs Invokana and Invokamet. The statement made note that, after what has been observed through adverse event reports, it appears that these drugs may decrease bone density in patients taking them, therefore increasing their risk of bone fractures. Warning labels on each of these drugs have linked them to possible bone fracture risks since their release to market. However, the FDA has required manufacturer Janssen Pharmaceuticals (a division of Johnson & Johnson corporation) to make an additional change to the warnings recently, in order to better indicate that these bone fractures are increasingly common among patients using Invokana when compared to patients using placebo pills.

The U.S. Food and Drug Administration commented on the possible ease of which these fractures can occur, stating, “Fractures were observed as early as 12 weeks after treatment initiation, and were more likely to be low trauma (e.g., arising after falls from no more than standing height) and affect the upper extremities.” The agency also brought up something else that was noted during drug studies: a significant decrease in overall bone mineral density among patients taking them. The FDA made note of a study which had evaluated 714 elderly patients. Among them, patients who took Invokana developed increased bone loss in their spine and hips.

The type-2 diabetes drug’s possible bone loss link is seen as a potential problem among other similar SGLT2 class inhibitor drugs as well, and has reportedly been monitored closely by the FDA for several years. In addition to the FDA’s recent comments, the Endocrinologic and Metabolic Drugs Advisory Committee issued a public safety communication to discuss bone fractures which had been observed following clinical trials on the drug the same year that it gained FDA approval and was sent to market, in 2013.

The attorneys of Banville Law are dedicated to keeping the public informed of important information regarding these drugs. To better accomplish this, they sponsor online resource website TheProductLawyers.com. They are also currently working to help ensure that anyone who has taken these types of diabetes drugs and who has suffered from medical problems will be provided the critical opportunity to investigate their legal rights in the matter. To help those interested in seeking justice, the attorneys of Banville Law are currently offering complimentary legal consultations for affected parties. These individuals could be entitled to substantial compensation through legal action.

To request additional Invokana information, or to ask questions, please contact the attorneys of Banville Law by calling 877-671-6480.

###

Contact TheProductLawyers.com:

Banville Law
877-671-6480
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60008778